Da-long Yang

He Di Rd 71
Nanning, 530021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008).

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008).

Journal: Scientific reports

Published: April 16, 2026

Reply to the Comment on the Article "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma".

Reply to the Comment on the Article "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma".

Journal: Liver cancer

Published: April 07, 2026

Reply to "Methodological Concerns in 'Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma'".

Reply to "Methodological Concerns in 'Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma'".

Journal: Liver cancer

Published: March 26, 2026

Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.

Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.

Journal: Liver cancer

Published: December 03, 2025

Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study.

Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study.

Journal: European journal of gastroenterology & hepatology

Published: September 18, 2025

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Journal: Liver cancer

Published: August 16, 2025

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Journal: Liver cancer

Published: July 18, 2025

Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study.

Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study.

Journal: European journal of gastroenterology & hepatology

Published: July 01, 2025

Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Journal: Hepatology (Baltimore, Md.)

Published: June 25, 2025

Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.

Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.

Journal: Hepatology (Baltimore, Md.)

Published: April 17, 2025

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).

Journal: JHEP reports : innovation in hepatology

Published: April 16, 2025

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).

Journal: Communications medicine

Published: February 05, 2025

Showing 1-12 of 19

Last Updated: 09/26/2026